$2.11 Billion is the total value of NEA Management Company, LLC's 47 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RARX | RA PHARMACEUTICALS INC | $288,094,000 | +98.4% | 6,138,797 | 0.0% | 13.62% | +13.3% | |
| ALLK | ALLAKOS INC | $216,294,000 | +21.3% | 2,268,188 | 0.0% | 10.23% | -30.7% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $127,322,000 | +48.6% | 2,090,678 | 0.0% | 6.02% | -15.1% | |
| RYTM | RHYTHM PHARMACEUTICALS INC | $112,787,000 | +6.3% | 4,912,306 | 0.0% | 5.33% | -39.3% | |
| EPZM | EPIZYME INC | $107,687,000 | +138.5% | 4,377,518 | 0.0% | 5.09% | +36.2% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $104,799,000 | +279.4% | 5,172,683 | 0.0% | 4.96% | +116.7% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $102,685,000 | +143.7% | 4,187,801 | 0.0% | 4.86% | +39.2% | |
| NET | CLOUDFLARE INC | $71,242,000 | -5.5% | 4,059,376 | 0.0% | 3.37% | -46.0% | |
| MRSN | MERSANA THERAPEUTICS INC | $68,552,000 | +262.7% | 11,963,649 | 0.0% | 3.24% | +107.2% | |
| DERM | DERMIRA INC | $53,161,000 | +137.3% | 3,506,649 | 0.0% | 2.51% | +35.5% | |
| GLYC | GLYCOMIMETICS INC | $48,081,000 | +22.7% | 9,089,041 | 0.0% | 2.27% | -29.9% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $40,593,000 | +46.5% | 6,643,704 | 0.0% | 1.92% | -16.3% | |
| SENS | SENSEONICS HOLDINGS INC | $28,417,000 | -7.1% | 30,888,266 | 0.0% | 1.34% | -46.9% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCadr | $18,999,000 | -20.5% | 15,832,611 | 0.0% | 0.90% | -54.6% | |
| OBSV | OBSEVA SA | $17,521,000 | -54.1% | 4,586,563 | 0.0% | 0.83% | -73.8% | |
| TRVI | TREVI THERAPEUTICS INC | $16,655,000 | -16.7% | 4,441,360 | 0.0% | 0.79% | -52.4% | |
| AVEO | AVEO PHARMACEUTICALS INC | $15,760,000 | -26.1% | 25,243,865 | 0.0% | 0.74% | -57.8% | |
| GNCA | GENOCEA BIOSCIENCES INC | $14,957,000 | -28.6% | 7,225,676 | 0.0% | 0.71% | -59.3% | |
| MRKR | MARKER THERAPEUTICS INC | $14,400,000 | -43.6% | 5,000,000 | 0.0% | 0.68% | -67.8% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $13,016,000 | +47.4% | 1,562,500 | 0.0% | 0.62% | -15.7% | |
| MLND | MILLENDO THERAPEUTICS INC | $11,908,000 | -5.2% | 1,766,779 | 0.0% | 0.56% | -45.9% | |
| SYBX | SYNLOGIC INC | $10,912,000 | +12.7% | 4,229,410 | 0.0% | 0.52% | -35.7% | |
| LQDA | LIQUIDIA TECHNOLOGIES INC | $10,640,000 | +20.2% | 2,486,062 | 0.0% | 0.50% | -31.4% | |
| BE | BLOOM ENERGY CORP | $9,960,000 | +129.9% | 1,333,333 | 0.0% | 0.47% | +31.2% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $9,886,000 | +37.9% | 2,382,286 | 0.0% | 0.47% | -21.4% | |
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $8,665,000 | -12.5% | 4,141,308 | 0.0% | 0.41% | -50.0% | |
| DZSI | DASAN ZHONE SOLUTIONS INC | $8,472,000 | -3.3% | 956,255 | 0.0% | 0.40% | -44.7% | |
| VRNA | VERONA PHARMA PLCads | $7,013,000 | +25.8% | 1,219,674 | 0.0% | 0.33% | -28.1% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $6,940,000 | +14.4% | 3,243,150 | 0.0% | 0.33% | -34.7% | |
| SURF | SURFACE ONCOLOGY INC | $6,232,000 | +32.4% | 3,315,149 | 0.0% | 0.30% | -24.4% | |
| CTIC | CTI BIOPHARMA CORP | $5,825,000 | +85.6% | 3,750,000 | 0.0% | 0.28% | +5.8% | |
| ERYP | ERYTECH PHARMA SAadr | $4,606,000 | +74.2% | 625,000 | 0.0% | 0.22% | -0.5% | |
| XFOR | X4 PHARMACEUTICALS INC | $3,567,000 | -15.8% | 333,333 | 0.0% | 0.17% | -51.9% | |
| TRVN | TREVENA INC | $3,205,000 | -13.1% | 3,811,691 | 0.0% | 0.15% | -50.2% | |
| TRILLIUM THERAPEUTICS INC | $2,163,000 | +234.8% | 2,100,000 | 0.0% | 0.10% | +92.5% | ||
| RGLS | REGULUS THERAPEUTICS INC | $1,827,000 | +23.6% | 2,052,455 | 0.0% | 0.09% | -29.5% | |
| AKTX | AKARI THERAPEUTICS PLCadr | $791,000 | +2.3% | 452,167 | 0.0% | 0.04% | -42.2% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $438,000 | -53.2% | 1,298,274 | 0.0% | 0.02% | -72.7% | |
| ELGX | ENDOLOGIX INC | $393,000 | -60.3% | 249,021 | 0.0% | 0.02% | -76.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-01-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.